Cargando…

Downregulated Mucosal Autophagy, Alpha Kinase-1 and IL-17 Signaling Pathways in Active and Quiescent Ulcerative Colitis

BACKGROUND: Improved mucosal immune profiling in active and quiescent colonic inflammatory bowel disease (IBD) is needed to develop therapeutic options for treating and preventing flares. This study therefore aimed to provide a comprehensive mucosal characterization with emphasis on immunological ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moraes Holst, Luiza, Halfvarson, Jonas, Carlson, Marie, Hedin, Charlotte, Kruse, Robert, Lindqvist, Carl Mårten, Bergemalm, Daniel, Almér, Sven, Bresso, Francesca, Ling Lundström, Maria, Repsilber, Dirk, D’Amato, Mauro, Keita, Åsa, Hjortswang, Henrik, Söderholm, Johan, Sundin, Johanna, Törnblom, Hans, Simrén, Magnus, Strid, Hans, Magnusson, Maria K, Öhman, Lena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343467/ https://www.ncbi.nlm.nih.gov/pubmed/35928254 http://dx.doi.org/10.2147/CEG.S368040

Ejemplares similares

Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Biological Therapy and Corticosteroids in Patients With Inflammatory Bowel Disease
por: Ling Lundström, Maria, et al.
Publicado: (2023)

Systemic Inflammatory Protein Profiles Distinguish Irritable Bowel Syndrome (IBS) and Ulcerative Colitis, Irrespective of Inflammation or IBS-Like Symptoms
por: Moraes, Luiza, et al.
Publicado: (2020)

Fecal Luminal Factors from Patients with Gastrointestinal Diseases Alter Gene Expression Profiles in Caco-2 Cells and Colonoids
por: Holst, Luiza Moraes, et al.
Publicado: (2022)

Symptoms compatible with functional bowel disorders are common in patients with quiescent ulcerative colitis and influence the quality of life but not the course of the disease
por: Mavroudis, Georgios, et al.
Publicado: (2019)

Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles
por: Andersson, Erik, et al.
Publicado: (2017)

Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register
por: Thunberg, Joel, et al.
Publicado: (2022)

Detailed Transcriptional Landscape of Peripheral Blood Points to Increased Neutrophil Activation in Treatment-Naïve Inflammatory Bowel Disease
por: Juzenas, Simonas, et al.
Publicado: (2022)

Fecal microbiota composition is linked to the postoperative disease course in patients with Crohn’s disease
por: Strömbeck, Anna, et al.
Publicado: (2020)

Fecal luminal factors from patients with irritable bowel syndrome induce distinct gene expression of colonoids
por: Iribarren, Cristina, et al.
Publicado: (2022)

Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study
por: Visuri, Isabella, et al.
Publicado: (2023)

A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin
por: Klingberg, Eva, et al.
Publicado: (2019)

A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome
por: Ahluwalia, Bani, et al.
Publicado: (2021)

Randomised controlled trial: effects of gluten‐free diet on symptoms and the gut microenvironment in irritable bowel syndrome
por: Algera, Joost P., et al.
Publicado: (2022)

Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study
por: Eriksson, Carl, et al.
Publicado: (2021)

Health-related quality of life in patients with long-standing ulcerative colitis in remission
por: Mavroudis, Georgios, et al.
Publicado: (2022)

Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis
por: Öhman, Lena, et al.
Publicado: (2021)

Maintaining work life under threat of symptoms: a grounded theory study of work life experiences in persons with Irritable Bowel Syndrome
por: Frändemark, Åsa, et al.
Publicado: (2022)

Fecal chromogranins and secretogranins are linked to the fecal and mucosal intestinal bacterial composition of IBS patients and healthy subjects
por: Sundin, Johanna, et al.
Publicado: (2018)

A novel stepwise integrative analysis pipeline reveals distinct microbiota-host interactions and link to symptoms in irritable bowel syndrome
por: Polster, Annikka, et al.
Publicado: (2021)

Elevated fecal peptidase D at onset of colitis in Galphai2(-/-) mice, a mouse model of IBD
por: Bergemalm, Daniel, et al.
Publicado: (2017)

Impaired Luminal Control of Intestinal Macrophage Maturation in Patients With Ulcerative Colitis During Remission
por: Maasfeh, Lujain, et al.
Publicado: (2021)

The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel Syndrome
por: Iribarren, Cristina, et al.
Publicado: (2021)

Habitual FODMAP Intake in Relation to Symptom Severity and Pattern in Patients with Irritable Bowel Syndrome
por: Nybacka, Sanna, et al.
Publicado: (2020)

Changes in serum and urinary metabolomic profile after a dietary intervention in patients with irritable bowel syndrome
por: Nybacka, Sanna, et al.
Publicado: (2021)

Type of Rectal Barostat Protocol Affects Classification of Hypersensitivity and Prediction of Symptom Severity in Irritable Bowel Syndrome
por: Josefsson, Axel, et al.
Publicado: (2022)

Prognostic Biosignatures at Ileocecal Resection: Hope or Reality?
por: Salomon, Benita, et al.
Publicado: (2021)

Evidence of altered mucosa-associated and fecal microbiota composition in patients with Irritable Bowel Syndrome
por: Sundin, Johanna, et al.
Publicado: (2020)

The Role of Carbohydrates in Irritable Bowel Syndrome: Protocol for a Randomized Controlled Trial Comparing Three Different Treatment Options
por: Nybacka, Sanna, et al.
Publicado: (2022)

Effects of the long-term storage of human fecal microbiota samples collected in RNAlater
por: Tap, Julien, et al.
Publicado: (2019)

Decreased Neutrophil Apoptosis in Quiescent ANCA-Associated Systemic Vasculitis
por: Abdgawad, Mohamed, et al.
Publicado: (2012)

Oat Bran Increased Fecal Butyrate and Prevented Gastrointestinal Symptoms in Patients With Quiescent Ulcerative Colitis—Randomized Controlled Trial
por: Nyman, Margareta, et al.
Publicado: (2020)

Randomised clinical trial: individual versus group hypnotherapy for irritable bowel syndrome
por: Lövdahl, Jenny, et al.
Publicado: (2022)

Irritable bowel syndrome with food‐related symptoms: Future directions in the clinical management
por: Melchior, Chloé, et al.
Publicado: (2022)

Gut Barrier Dysfunction—A Primary Defect in Twins with Crohn’s Disease Predominantly Caused by Genetic Predisposition
por: Keita, Åsa V, et al.
Publicado: (2018)

Association between Brachyspira and irritable bowel syndrome with diarrhoea
por: Jabbar, Karolina S, et al.
Publicado: (2021)

Diet and gut microbiome interactions of relevance for symptoms in irritable bowel syndrome
por: Tap, Julien, et al.
Publicado: (2021)

Predictors of Symptom-Specific Treatment Response to Dietary Interventions in Irritable Bowel Syndrome
por: Colomier, Esther, et al.
Publicado: (2022)

Associations among neurophysiology measures in irritable bowel syndrome (IBS) and their relevance for IBS symptoms
por: Midenfjord, Irina, et al.
Publicado: (2020)

Fasting breath H(2) and gut microbiota metabolic potential are associated with the response to a fermented milk product in irritable bowel syndrome
por: Le Nevé, Boris, et al.
Publicado: (2019)

Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
por: Eriksson, Carl, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0lsht4f7apdjmn4ru5vd9l16jh